Real‐World Efficacy and Safety of Setmelanotide in Adults With Monogenic or Syndromic Obesity: A Prospective Cohort Study
Obesity · 2025
DOI: 10.1002/oby.70002 ↗At a glance
Kohortenstudie in Obesity, 2025. Written by Francois Mifsud and 7 co-authors. Institution: Assistance Publique Hôpitaux de Paris, Service de Nutrition, Centre Référent PRADORT "Syndrome de Prader-Willi et Autres Obésités Rares Avec Troubles…. Major MEDLINE topics: alpha-MSH, Obesity, Anti-Obesity Agents. Cited 8 times so far (Crossref); 44 references.
Abstract (original language)
Objective
The melanocortin‐4 receptor agonist setmelanotide has demonstrated effectiveness in phase 3 clinical trials for patients with monogenic obesity caused by biallelic variants in the leptin receptor (LEPR) and pro‐opiomelanocortin (POMC), as well as for individuals with Bardet–Biedl syndrome (BBS). However, real‐world evidence remains limited. This study evaluates the long‐term effectiveness and safety of setmelanotide in patients who received treatment under a pre‐marketing early‐access authorization.
Methods
This ongoing prospective monocentric cohort includes 17 patients with obesity due to BBS ( n = 11) or biallelic variants in LEPR ( n = 4) or POMC ( n = 2) who either started setmelanotide in routine care between 2022 and 2024 or continued therapy after participating in the RM‐493‐022 clinical trial. The average follow‐up time was 14.4 months.
Results
Patients experienced a clinically significant weight reduction of 20% from their highest pre‐treatment weight within the first year. Those previously treated in a clinical trial maintained their weight loss over time. Additionally, eating behavior improved, with significant reductions in hunger (−62%), food craving (−41%), and external eating evaluated by DEBQ. The overall safety profile was consistent with phase 3 trials data, without any new safety signals.
Conclusions
These findings confirm the drug's long‐term clinical benefit and safety profile in a routine‐care setting.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Assistance Publique Hôpitaux de Paris, Service de Nutrition, Centre Référent PRADORT "Syndrome de Prader-Willi et Autres Obésités Rares Avec Troubles du Comportement Alimentaire," Hôpital Pitié-Salpêtrière, Paris, Franc…
- Sorbonne Université, Inserm, Nutrition et Obésités: Approches Systémiques, Nutriomique, Paris, France.
- Laboratoires de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, IGMA (Institut de Génétique Médicale d'Alsace), Université de Strasbourg, Strasbourg, France.
- UF de Génétique de l'Obésité et des Dyslipidémies, Service de Biochimie Endocrinienne et Oncologique, AP-HP Sorbonne Université, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
ORCID profiles: Francois Mifsud, Jean Muller
Cite
APA
Mifsud, F., Chalopin, S., Guillon, E., Faucher, P., Muller, J., Le Bihan, J., Clément, K., & Poitou, C. (2025). Real‐World Efficacy and Safety of Setmelanotide in Adults With Monogenic or Syndromic Obesity: A Prospective Cohort Study. Obesity. https://doi.org/10.1002/oby.70002
Vancouver
Mifsud F, Chalopin S, Guillon E, Faucher P, Muller J, Le Bihan J, et al. Real‐World Efficacy and Safety of Setmelanotide in Adults With Monogenic or Syndromic Obesity: A Prospective Cohort Study. Obesity. 2025. doi:10.1002/oby.70002
BibTeX
@article{Mifsud2025,
author = {Mifsud, Francois and Chalopin, Sarah and Guillon, Emilie and Faucher, Pauline and Muller, Jean and Le Bihan, Johanne and Clément, Karine and Poitou, Christine},
title = {Real‐World Efficacy and Safety of Setmelanotide in Adults With Monogenic or Syndromic Obesity: A Prospective Cohort Study},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.70002}
}
EUVIMED